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Abstract
Despite recent advances, acute respiratory distress syndrome (ARDS) remains
a severe and often fatal disease for which there is no therapy able to reduce
the underlying excessive lung inflammation or enhance resolution of injury.
Metabolic programming plays a critical role in regulating inflammatory
responses. Due to their high metabolic needs, neutrophils, macrophages, and
lymphocytes rely upon glutamine metabolism to support activation and func-
tion. Additionally, during times of physiologic stress, nearly all cells, including
fibroblasts and epithelial cells, require glutamine metabolism. We hypothesized
that inhibiting glutamine metabolism reduces lung inflammation and pro-
motes resolution of acute lung injury. Lung injury was induced by instilling
lipopolysaccharide (LPS) intratracheally. To inhibit glutamine metabolism, we
administered a glutamine analogue, 6-diazo-5-oxo-L-norleucine (DON) that
binds to glutamine-utilizing enzymes and transporters, after injury was well
established. Treatment with DON led to less lung injury, fewer lung neu-
trophils, lung inflammatory and interstitial macrophages, and lower levels of
proinflammatory cytokines and chemokines at 5 and/or 7 days after injury.
Additionally, DON led to earlier expression of the growth factor amphiregulin
and more rapid recovery of LPS-induced weight loss. Thus, DON reduced
lung inflammation and promoted resolution of injury. These data contribute
to our understanding of how glutamine metabolism regulates lung inflamma-
tion and repair, and identifies a novel target for future therapies for ARDS
and other inflammatory lung diseases.
Introduction
Acute respiratory distress syndrome (ARDS) is a severe,
often fatal syndrome characterized by excessive lung
inflammation and damage to the alveolar-capillary barrier
(Ware and Matthay 2000; Piantadosi and Schwartz 2004).
Current treatment for ARDS focuses on supportive care,
and there are no treatments able to target the underlying
inflammation and alveolar damage (Zeiher et al. 2004;
Steinberg et al. 2006; Liu et al. 2008; National Heart et al.
2014). Thus, there is a critical need for understanding
mechanisms underlying resolution of lung injury and for
novel approaches to modulate the processes that regulate
resolution.
Metabolic programming is one of the important mech-
anisms by which immune responses are regulated. During
times of physiologic stress, glutamine utilization increases
considerably, and glutamine becomes an essential nutrient
(Wilmore and Shabert 1998). In critical illness, a decrease
in serum glutamine level is associated with increased
mortality (Oudemans-van Straaten et al. 2001). Thus, glu-
tamine supplementation has been investigated as a
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treatment for critical illnesses such as ARDS and sepsis.
However, results have been heterogeneous. Some animal
studies looking at glutamine supplementation in models
of acute lung injury (ALI) induced by abdominal sepsis,
lipopolysaccharide (LPS), or acid aspiration found that
glutamine given prior to the development of injury or
within the first hour of injury attenuated the development
of lung injury over the first 24 h (Singleton et al. 2005;
Zhang et al. 2009; Lai et al. 2014). In contrast, another
study found that glutamine supplementation prior to
LPS-induced ALI led to increased lung injury at both
24 h and 2 weeks (Hou et al. 2009). When critically ill
patients were treated with glutamine supplementation, the
results have been mixed (Andrews et al. 2011; Werner-
man et al. 2011; Heyland et al. 2013). Although the pri-
mary outcome is not identical in these studies, one study
suggested glutamine did not affect the measured out-
comes, one suggested that ICU mortality was less, and the
third showed that mortality was actually increased follow-
ing glutamine supplementation.
One explanation for these seemingly contradictory
results is that the role of glutamine may vary depending
on the phase of injury. In vitro studies show that glu-
tamine potentiates the activity of inflammatory cells, pro-
moting activation and function of neutrophils and
macrophages and proliferation and differentiation of lym-
phocytes (Wallace and Keast 1992; Wells et al. 1999; Fur-
ukawa et al. 2000; Pithon-Curi et al. 2003; Carr et al.
2010; Nakaya et al. 2014). Thus, in patients with ongoing,
excessive inflammation, glutamine may in fact be fueling
that inflammatory response and increasing disease sever-
ity. Studies in models of other inflammatory diseases have
found that inhibiting glutamine metabolism can reduce
inflammation, promote immunological tolerance, and
improve survival (Gordon et al. 2015; Lee et al. 2015;
Potter et al. 2015).
We hypothesized that in ALI, glutamine metabolism
promotes excessive inflammation and that inhibition of
glutamine metabolism reduces inflammation and
promotes resolution of injury. To inhibit glutamine
metabolism, we utilized a glutamine analogue, 6-diazo-5-
oxo-L-norleucine (DON), which binds to and inhibits
glutamine-utilizing enzymes and transporters, blocking
glutamine metabolism and uptake into cells (Pinkus
1977). To study resolution of injury, we began adminis-
tering DON 2 days after induction of ALI. We found
that inhibition of glutamine metabolism with DON accel-
erated resolution of ALI, reducing lung inflammation
and promoting expression of the growth factor
amphiregulin (AREG). Our data reveal the critical role of
glutamine in promoting inflammation and injury in ALI




C57BL/6 mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME) and housed at the University of
North Carolina animal facility. Mice aged 8 to 10 weeks
old were utilized for experiments, and each experiment
was age and sex matched. Weight was monitored daily,
and mice that demonstrated ≥ 25% weight loss for two
consecutive days were euthanized. All animal protocols
were approved by the University of North Carolina at
Chapel Hill School of Medicine Institutional Animal Care
and Use Committee.
Initiation of lung injury
To determine the role of glutamine metabolism in ALI,
we utilized an established model of lung injury and
repair. Mice were anesthetized with tribromoethanol prior
to orotracheal intubation with a 20-gauge catheter as pre-
viously described (Dial et al. 2017). Escherichia coli LPS
O55:B5 (7.5 mg/kg) (Sigma-Aldrich, St. Louis, MO) was
then instilled intratracheally (IT) via the 20-gauge cathe-
ter. Control mice received an equal volume of vehicle.
The mice were immediately extubated and allowed to
awaken. DON (1.6 mg/kg, Sigma-Aldrich, St. Louis, MO)
was administered intraperitoneally (IP) on days 2, 4, and
6 following LPS administration (Lee et al. 2015). Control
mice received an equal volume of vehicle. At 5 and 7 days
Figure 1. Inhibition of glutamine metabolism with DON accelerates resolution of established ALI. C57BL/6 mice (N = 20 per control group, 42–
44 per LPS group) received LPS (7.5 mg/kg IT) or vehicle control on day 0 to induce ALI, followed by DON (1.6 mg/kg IP) or vehicle on days 2,
4, and 6 (indicated by arrows). (A) Change in weight from baseline following LPS. Significance was determined by multiple t-tests with
Holmes–Sidak correction. **P < 0.01 compared to mice given LPS followed by vehicle. (B) Survival curve following LPS-injury. P = 0.64 by Log-
rank test. (C) BAL protein on days 5 and 7 following LPS. N = 10 per control group and 15-22 per LPS group. Error bars represent one
standard deviation. Significance was determined by two-way ANOVA followed by Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01. (D)
Representative samples of H&E-stained lung histology from uninjured mice and three DON- and three vehicle-treated injured mice at day 5
(n = 5 per treatment). Gray scale bar indicates 2 mm; black-scale bar indicates 200 lm.
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after injury, mice were euthanized by isoflurane overdose
and exsanguination from the inferior vena cava.
BAL collection and protein measurement
Bronchoalveolar lavage (BAL) fluid was collected by intu-
bating the trachea with a 20-gauge catheter and performing
two lavages, each with 750 lL of PBS. BAL fluid was cen-
trifuged at 500g for 5 min. The supernatant was separated
for measurement of protein by DCTM protein assay (Bio-
Rad, Hercules, CA) as per the manufacturer’s protocol.
Flow cytometry
Lung tissue was processed to form a single cell suspension
and immunostained to identify cell types as previously
described (Dial et al. 2017). Antibodies were obtained
from Biolegend (San Diego, CA): CD45 FITC (clone 30-
F11), SiglecF PE (clone E50-2440), Annexin V PerCP-
Cy5.5 (catalog 640936), CD64 PE-Cy7 (clone X54-5/7.1),
Ly6G APC (clone 1A8), CD3 FITC (clone 145-2C11),
CD45 Alexa Fluor 700 (clone 30-F11), CD4 PB (clone
GK1.5), Foxp3 Alexa Fluor 647 (clone 150D), Zombie
AquaTM (catalog 423102); from BD Horizon (Waltham,
MA): Ly6C BV421 (clone AL-21); and from BD Pharmin-
gen (Waltham, MA): CD16/CD32 Mouse BD Fc blockTM
(clone 2.462). eBioscience (Waltham, MA) fixation/per-
meabilization reagents were used. The cells were examined
using flow cytometry (Cytoflex, Beckman Coulter, Brea
CA) and analyzed using CytExpert (Beckman Coulter)
software.
Quantitative RT-PCR
Cell pellets of homogenized lung tissue were snap-frozen at
80°C, and RNA was extracted using Qiagen miRNeasy
Mini Kit (Hilden, Germany) according to the manufac-
turer’s protocol. cDNA was produced using the Bio Rad
iScript cDNA synthesis kit per the manufacturer’s instruc-
tions. qRT-PCR was performed, using PrimeTime Gene
Expression Master Mix (Integrated DNA Technologies,
Skokie, IL) on a QuantStudio 6 Flex (Applied Biosystems
by Life Technologies, Waltham, MA) and normalized to
18s (Life Technologies). Taqman probes were purchased
from Thermo Fisher Scientific (Waltham, MA) for TNF-a,
IL-6, IL-1b, AREG, KGF, CXCL1, and CCL2.
Histology
Lungs were inflated with formalin to 22 cm H2O atmo-
spheric pressure. Tissue blocks were embedded in paraf-
fin, sectioned at 4–5 lm, and stained with H&E stain by
the UNC Animal Histopathology & Lab Medicine Core.
Statistics
Statistical analysis was performed using GraphPad Prism
7.03 software (La Jolla, CA). Mortality differences were
analyzed by the log-rank test. To compare means between
two groups, Student’s t-tests with Holm-Sidak correction
were performed. To compare more than two groups,
two-way ANOVA was used, followed by Tukey’s, or Dun-
nett’s correction for multiple comparisons. Statistical dif-
ference was accepted at P < 0.05.
Results
Inhibition of glutamine metabolism with
DON accelerates resolution of established
ALI
C57BL/6 mice received LPS or vehicle control on day 0
to induce ALI. Mice then received either DON or vehi-
cle on days 2, 4, and 6. Following LPS administration,
both DON- and vehicle-treated mice lost a significant
amount of weight (Fig. 1A). For vehicle-treated mice,
weight loss persisted through days 2–5, and mice began
to gain weight on days 6–7. However, DON-treated
mice demonstrated accelerated recovery of body weight,
with significantly greater weight on day 5 and a trend
toward greater weight on day 7 (P = 0.06). There was
no difference in survival between the DON-treated and
untreated groups (P = 0.64) (Fig. 1B). Weight data for
mice that did not survive were included until the time
of death; however, other data were not included in the
analysis.
Following LPS injury, there was increased protein in
BAL fluid on days 5 and 7; however, in the DON-treated
mice, BAL protein was only elevated on day 5, and there
was no significant elevation in BAL protein on day 7
(Fig. 1C). Lung histology was assessed on day 5 following
LPS injury, and DON-treated mice demonstrated less
lung inflammation by H&E staining (Fig. 1D).
Inhibition of glutamine metabolism with
DON in established ALI reduces lung
inflammatory cells
We characterized the inflammatory infiltrate within the
lungs by flow cytometric analysis of immunostained lung
digests. On days 5 and 7 following LPS administration,
there was an increase in the number of cells within the
lungs, primarily neutrophils (CD45 + Ly6G+) and macro-
phages (CD45+Ly6G-CD64+) on day 5 and macrophages
and CD4+ T cells (CD45+CD3+CD4+) on day 7
(Fig. 2A–D). Treatment with DON beginning at 48 hours
after initiation of ALI, when inflammation and injury are
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well established, resulted in fewer lung neutrophils on day
5 and fewer macrophages on days 5 and 7. There was no
statistical difference in the number of CD4 + T cells
between mice receiving DON or vehicle after LPS injury.
In contrast, the number of lung regulatory T cells
(CD45+CD4+Foxp3+) increased on days 5 and 7 follow-
ing LPS; however, this increase was not affected by DON
treatment (Fig. 2E).
Figure 2. Inhibition of glutamine metabolism with DON in established ALI reduces lung inflammatory cells. Lungs were analyzed on days 5 and
7 by flow cytometry to determine the number of (A) lung cells, (B) neutrophils, (C) macrophages, (D) CD4+ T cells, and (E) Tregs. N = 10 per
control group and 15–22 per LPS group. Error bars represent one standard deviation. Significance was determined by two-way ANOVA
followed by Tukey’s multiple comparisons test (A–C) or Dunnett’s multiple comparisons test (D–E). *P < 0.05, **P < 0.01, ***P < 0.001.
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We then further characterized lung macrophages by
flow cytometry, identifying alveolar macrophages (CD
45 + Ly6G-CD64 + SiglecF+), inflammatory macrophages
(CD45+Ly6G-CD64+Ly6C+), and interstitial macrophages
(CD45+Ly6G-CD64+Ly6C-SiglecF-). Following LPS injury,
there was an increase in the number of all three macro-
phage subpopulations on days 5 and 7 (Fig. 3). DON
treatment resulted in fewer inflammatory macrophages on
day 5 and fewer interstitial macrophages on day 7
(Fig. 3A–B). DON did not affect the number of alveolar
macrophages following LPS injury (Fig. 3C).
DON alters expression of cytokines,
chemokines, and growth factors within the
lungs
In addition to characterizing the inflammatory infiltrate
by flow cytometry, we measured mRNA expression of
proinflammatory cytokines and chemokines within lung
tissue by qRT-PCR to characterize further the
inflammatory response following LPS and to determine
the impact of DON on these mediators. LPS increased
expression of genes coding for TNF-a, IL-6, CXCL1, and
CCL2 at days 5 and 7 but did not impact on the
expression of IL-1b mRNA (Fig. 4A–E). DON resulted
in lower levels of expression of TNF-a, IL-6, and CCL2
on day 7. DON had no impact on the levels of IL-1b or
CXCL1.
To determine the mechanism through which DON
may be acting to aid resolution of lung injury, we mea-
sured mRNA expression of two growth factors that have
been shown to be important in resolution of ALI: AREG
and keratinocyte growth factor (KGF) (Shyamsundar
et al. 2014; Xu et al. 2016; Ogata-Suetsugu et al. 2017).
After LPS administration, expression of AREG within the
lungs increased on day 7 (Fig. 5A). With DON treatment,
this increase in AREG expression occurred earlier, on day
5. In contrast, KGF expression did not change following
LPS injury; however, it was increased in uninjured mice
receiving DON from days 2–7 (Fig. 5B).
Figure 3. Inhibition of glutamine metabolism with DON in established ALI alters lung macrophage phenotypes. Lungs were analyzed on day 5
and 7 by flow cytometry to quantify (A) inflammatory macrophages, (B) interstitial macrophages, (C) alveolar macrophages. N = 10 per control
group and 15–22 per LPS group. Error bars represent one standard deviation. Significance was determined by two-way ANOVA followed by
Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001.
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Discussion
Metabolic programming is an important regulator of
inflammatory responses. Our study reveals the critical role
of glutamine in regulating lung inflammation and repair
in ALI. Prior in vitro work has shown that glutamine
metabolism promotes activation and function of neu-
trophils and macrophages and proliferation and
Figure 4. DON alters expression of cytokines, chemokines, and growth factors when given to established ALI. mRNA expression of cytokines
and chemokines within lung tissue by qRT-PCR on days 5 and 7 following LPS administration and DON treatment. (A) TNF-a, (B) IL-6, (C) CCL2,
(D) CXCL1, (E) IL-1b. N = 10 per control group and 15–22 per LPS group. Error bars represent one standard deviation. Statistical significance
was determined with two-way ANOVA followed by Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001.
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differentiation of lymphocytes (Wallace and Keast 1992;
Wells et al. 1999; Furukawa et al. 2000; Pithon-Curi et al.
2003; Carr et al. 2010; Nakaya et al. 2014). In fact, glu-
tamine is utilized by nearly all cell types, and their relative
need for glutamine and its metabolites may vary. We
hypothesized that in LPS-induced ALI, glutamine pro-
motes inflammation and that inhibiting glutamine meta-
bolism attenuates the inflammatory response and
accelerates lung injury resolution.
Our study found that inhibition of glutamine metabo-
lism with DON accelerated recovery from LPS-induced
ALI, as documented by accelerated weight recovery, less
protein in BAL fluid, and less lung inflammation. Further,
DON altered the inflammatory response, reducing the
number of neutrophils, inflammatory macrophages, and
interstitial macrophages; reducing expression of the
proinflammatory cytokines and chemokines TNF-a, IL-6,
and CCL2; and promoting expression of the prorepair
growth factor AREG. These data support our hypothesis
and reveal the important role that glutamine plays in reg-
ulating inflammation.
Our data suggest that inhibition of glutamine metabo-
lism with DON accelerates resolution of established LPS-
induced ALI due to both dampening inflammation and
enhanced resolution of injury. Prior in vitro studies have
shown that glutamine regulates neutrophil and macro-
phage activity. Glutamine supplementation delays neu-
trophil apoptosis, enhances production of reactive oxygen
species, and is necessary for phagocytosis (Furukawa et al.
2000; Pithon-Curi et al. 2003). Within macrophages, glu-
tamine promotes production of inflammatory cytokines
such as TNF-a and IL-6 (Wallace and Keast 1992; Wells
et al. 1999). In contrast, Tregs do not require glutamine
metabolism (Nakaya et al. 2014), and we found no differ-
ence in the number of Tregs within the lungs with DON
treatment. Furthermore, glutamine does not impact on
Figure 5. DON promotes expression of AREG but not KGF when given to established ALI. mRNA expression of (A) AREG and (B) KGF within
lung tissue by qRT-PCR on days 5 and 7 following LPS-induced ALI and DON treatment. N = 10 per control group and 15-22 per LPS group.
Error bars represent one standard deviation. Statistical significance was determined with two-way ANOVA followed by Dunnett’s multiple
comparisons test (A) or Tukey’s multiple comparisons test (B). *P < 0.05, **P < 0.01, ***P < 0.001.
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alveolar macrophages, an anti-inflammatory macrophage
subpopulation that decreases in number during the acute
inflammatory response but then recovers. Thus, DON
appears to alter the inflammatory milieu of the lung,
affecting proinflammatory macrophages and neutrophils
while not impacting Tregs, which mediate resolution of
ALI (D’Alessio et al. 2009). Whether glutamine inhibition
acts solely to dampen the function and clearance of
inflammatory cells or whether this inhibition also acts to
suppress recruitment of any additional neutrophils and
inflammatory macrophages from the circulation at days
3–5 remains to be determined.
One of the other effects of DON found in our study
was accelerated production of AREG. AREG is a growth
factor in the epidermal growth factor family that pro-
motes tissue repair following injury (Zaiss et al. 2013). In
models of lung injury, it is produced by macrophages,
regulatory T cells, and type 2 innate lymphoid cells
(Monticelli et al. 2011; Arpaia et al. 2015; Xu et al. 2016).
Prior studies have found that AREG promotes epithelial
repair in LPS-induced ALI and influenza infection, and
in vitro studies have shown that it enhances regulatory T
cell activity (Monticelli et al. 2011; Zaiss et al. 2013;
Arpaia et al. 2015; Xu et al. 2016; Ogata-Suetsugu et al.
2017). In fact, administration of an antibody to neutralize
AREG worsens LPS-induced ALI, whereas administration
of exogenous AREG ameliorates lung injury (Xu et al.
2016; Ogata-Suetsugu et al. 2017). Thus, by increasing
expression of AREG more rapidly after injury, we postu-
late that DON enhances resolution of ALI.
In conclusion, metabolic programming is an important
regulator of inflammatory responses. Our study reveals
the important role of glutamine metabolism in regulating
lung inflammation and resolution. To our knowledge, this
is the first study to demonstrate that inhibiting glutamine
metabolism after inflammation and injury are established
leads to accelerated resolution of ALI by reducing lung
inflammation and promoting production of the growth
factor AREG. These data contribute to our understanding
of how glutamine metabolism regulates lung inflamma-
tion and repair, and identifies a novel target for future
therapies for ARDS and other inflammatory lung diseases.
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